Meridian Bioscience — Q3 FY2020 Earnings Presentation
13 slides from Meridian Bioscience's earnings presentation, Aug 7, 2020
Slide 1: FY2020 Q3 Results
FY2020 Q3 Results August 7, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements Safe Harbor
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A
Slide 3: Non-GAAP Financial Measures
Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and earnings per diluted share, excluding as applicable the effects of acquisition-related costs, a change in fair value of contingent consideration obligation, res
Slide 4: Q3 FY2020 Business Highlights
Life Science COVID-19 related products drive record growth Completed assay design lock for Revogene® COVID-19 assay Re-initiated clinical trials for three key GI products Closed acquisition of Exalenz – Integrated commercial team Q3 FY2020 Business Highlights Diagnostics Life Science
Slide 5: FY2020 Third Quarter Earnings Summary
FY2020 Third Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2020 FY2019 Change Revenue $84,797 $48,440 +75% Gross Margin % 65.9% 58.3% +7.6 pts Operating expenses(1) Ratio $25,443 30.0% $19,343 39.9% +32% -9.9 pts Operating income Margin % $30,409 35.9% $8,916 18.4%
Slide 6: FY2020 Third Quarter Operating Segment Highlights
FY2020 Third Quarter Operating Segment Highlights ($000’s) Diagnostics (Adjusted Non-GAAP) FY2020 FY2019 Change Revenue $21,598 $33,118 -35% Operating income Margin % ($7,118) NMF $7,103 21.4% NMF NMF Diagnostics revenue by: Technology: Molecular assays $3,182 $5,894 -46% Non-molecular assays 18,416
Slide 7: FY2020 Fiscal Year Guidance
FY2020 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Prior Guidance Updated FY2020 Guidance Meridian Bioscience Consolidated net revenues: $245 to $250 Million Adjusted operating margin: 22% to 23% Adjusted earnings per share*: $1.01 to $1.05 Diagnostics Net revenues: $118 to $12
Slide 8: Exalenz
EXALENZ ~~
Slide 9: Exalenz Integration Update
Operational leadership retained and integrated Commercial organization fully integrated with Meridian Executed virtual sales training on BreathID® First BreathID® Smart System placed in fiscal Q3 Exalenz Integration Update
Slide 10: The BreathID Smart Advantage
Unparalleled Performance Most accurate test on market with 100% sensitivity Intuitive Efficiency Fully automated process, 2 minutes per test with an intuitive, user-friendly touchscreen for optimal process management Trusted H. pylori Partner Full portfolio suited to physician choice Compact Benchto
Slide 11: COVID-19
COVID-19 ~~
Slide 12: Life Science "Shots on Goal"
Life Science “Shots on Goal” PCR Antibody Antigen Molecular Immunological Less More TBD More Less TBD Neutral Zero TBD 35+ Approved assays 10+ Approved assays TBD Americas EMEA ROW Americas Jan Feb Mar Apr May Jun Jul New COVID-19 Cases (7 Day Rolling Avg) Source: European Center for Disease Prevent
Slide 13: Contact
Contact: [email protected]
Meridian Bioscience — Q3 FY2020 Earnings Presentation on 6ix